

# Diagnostic Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy Number: DIAGNOSTIC 109.1 T2  
Effective Date: October 1, 2022

[➔ Instructions for Use](#)

Table of Contents	Page
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Applicable Codes</a> .....	1
<a href="#">Description of Services</a> .....	2
<a href="#">Clinical Evidence</a> .....	2
<a href="#">U.S. Food and Drug Administration</a> .....	4
<a href="#">References</a> .....	4
<a href="#">Policy History/Revision Information</a> .....	4
<a href="#">Instructions for Use</a> .....	5

Related Policies
None

## Coverage Rationale

[➔ See Benefit Considerations](#)

The following dynamic spinal visualization techniques when used to visualize movement of the back or spine are unproven and not medically necessary due to insufficient evidence of efficacy.

- Digital motion x-ray of the spine
- Cineradiography/videofluoroscopy

Vertebral motion analysis is unproven and not medically necessary due to insufficient evidence of efficacy.

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies may apply.

CPT Code	Description
76120	Cineradiography/video radiography, except where specifically included
76125	Cineradiography/video radiography to complement routine examination (List separately in addition to code for primary procedure)
76496	Unlisted fluoroscopic procedure (e.g., diagnostic, interventional) [when specified as videofluoroscopy]
76499	Unlisted diagnostic radiographic procedure
0693T	Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report

*CPT® is a registered trademark of the American Medical Association*

## Description of Services

Dynamic spinal visualization is a general term addressing different imaging technologies that simultaneously visualize spine (vertebrae) movements and external body movement.

Digital motion x-ray involves the use of either film x-ray or computer-based x-ray 'snapshots' taken in sequence as an individual moves in front of an x-ray camera. Film x-rays are digitized into a computer for manipulation while computer-based x-rays are automatically created in a digital format. The digitized snapshots are then put in order using a computer program and played on a video monitor, creating a moving image of the inside of the body. This moving image can then be evaluated by a physician alone or by using a computer that evaluates several aspects of the body's structure to determine the presence or absence of abnormalities.

Videofluoroscopy and cineradiography are different names for the same procedure that uses fluoroscopy to create real-time video images of internal body structures. Videofluoroscopy works like a video camera, providing motion pictures of the inside of the body. The results of these techniques can be displayed on a video monitor as the procedure is being conducted. They can also be viewed or digitally analyzed at a later time.

Vertebral motion analysis systems provide assisted bending with fluoroscopic imaging and computerized analysis. The device uses facial recognition software to track vertebral bodies across the images. Proposed benefits of the vertebral motion analysis are a reduction in patient-driven variability in bending and assessment of vertebral movement across the entire series of imaging rather than at the end range of flexion and extension bending with fluoroscopic imaging and computerized analysis.

## Clinical Evidence

### Cineradiography/Video Radiography

The current literature evaluating the clinical utility of dynamic spinal visualization techniques, including but not limited to digital motion x-ray and cineradiography (video fluoroscopy), for the evaluation and assessment of the spine is limited to a few studies (Lee et al., 2002; Teyhen et al., 2007; O'Sullivan et al., 2012; Yaeger et al., 2014; Qu et al., 2019) involving small numbers of participants. While these studies do indicate that there may be some benefit from the use of these technologies, further evidence from large, controlled trials is needed to demonstrate that the results have significant impact on clinical care and are superior to currently available alternatives.

Knippenberg et al. (2017) conducted a systematic review to investigate 1) which markerless motion capture systems (MCS) are used as training devices in neurological rehabilitation, 2) how they are applied, 3) in which target population, 4) what the content of the training and 5) efficacy of training with MCS. A computerized systematic literature review was conducted in four databases (PubMed, Cinahl, Cochrane Database and IEEE). The Van Tulder's Quality assessment was used to score the methodological quality of the selected studies. The descriptive analysis is reported by MCS, target population, training parameters and training efficacy. Eighteen studies were selected (mean Van Tulder score =  $8.06 \pm 3.67$ ). Based on methodological quality, six studies were selected for analysis of training efficacy. The most commonly used MCS was Microsoft Kinect, training was mostly conducted in upper limb stroke rehabilitation. Training programs varied in intensity, frequency, and content. None of the studies reported an individualized training program based on client-centered approach. The investigators concluded that markerless motion capture systems have the potential in neurological rehabilitation to increase the motivation during training and may assist improvement on one or more International Classification of Functioning, Disability and Health (ICF) levels. Future technological developments should take up the challenge to combine markerless MCS with the principles of a client-centered task-oriented approach and prove efficacy using randomized controlled trials (RCTs) with long-term follow-up. According to the investigators, because there are few RCTs and controlled clinical trials and few studies with long-term follow-up, it is difficult to prove efficacy of markerless MCS based on the studies included in this review.

Springer and Seligmann (2016) evaluated the literature describing the concurrent validity of using the Kinect as a gait analysis instrument. The Kinect consists of an array of sensors, including a camera and a depth sensor, enabling the Kinect to track and record 3D human motion without using controllers or markers. An online search of PubMed, CINAHL, and ProQuest databases was performed. Included were studies in which walking was assessed with the Kinect and another gold standard device and consisted of at least one numerical finding of spatiotemporal or kinematic measures. The search identified 366 papers, from which 12 relevant studies were retrieved. The results demonstrate that the Kinect is valid only for some spatiotemporal gait

parameters. Although the kinematic parameters measured by the Kinect followed the trend of the joint trajectories, they showed poor validity and large errors. The authors concluded that Kinect may have the potential to be used as a tool for measuring spatiotemporal aspects of gait, yet standardized methods should be established, and future examinations with both healthy subjects and clinical participants are required in order to integrate the Kinect as a clinical gait analysis tool.

## Vertebral Motion Analysis

For individuals who have back or spine pain who receive vertebral motion analysis, the evidence includes comparisons to standard flexion/extension radiographs. These studies reported that vertebral motion analysis reduces variability in measurement of rotational and translational spine movement compared with standard flexion/extension radiographs. Whether the reduction in variability improves diagnostic accuracy or health outcomes is uncertain. The evidence is insufficient to determine if the effects of the technology will positively impact clinical health outcomes.

Hurley et al. (2021) compared leg length measurements (LLM) and varus/valgus knee measurements (VVM) performed clinically, radiologically and using markerless motion analysis (MMA) in patients being assessed for potential total knee replacement (TKR). Twenty-three patients awaiting unilateral primary TKR were included in the study. According to the authors, the most important finding of this study was that significant differences were reported between results obtained for calculating LLM and VVM clinically, radiologically and using MMA. As much of the literature has previously validated the use of clinical and radiological in obtaining LLM, this study poses the question as to whether the results obtained using MMA for LLM and VVM can be utilized.

van Kersbergen et al. (2021) investigated whether a consumer depth camera can capture changes in gait features of Parkinson's patients. The dataset consisted of 19 patients (tested in both a practically defined OFF phase and ON phase) and 8 controls, who performed the "Timed-Up-and-Go" test multiple times while being recorded with the Microsoft Kinect V2 sensor which records Red-Green-Blue (RGB)-depth data and tracks 25 anatomical landmarks in 3D space without the need for body-attached sensors or markers. Camera-derived features were step length, average walking speed and mediolateral sway. Motor signs were assessed clinically using the Movement Disorder Society Unified Parkinson's Disease Rating Scale. The authors were able to detect group differences in gait features between people with PD and healthy controls using the Kinect depth camera. However, the current task setup and analysis approach lacks sensitivity to detect small intra-individual changes in symptom severity. According to the authors, limitations of this study include the small sample size, subjects with relatively mild symptoms and a not complete age match with the control population. The standard outcome for the TUG (task duration) could not be analyzed because of missing frames at the beginning of the recording.

In a clinical case study, Schroeder et al. (2020) evaluated whether a markerless system for three-dimensional motion capture from RGB depth sequences using a whole-body infant model can serve as the basis for automated General Movement Assessment (GMA). The 29 high risk infants that were included in the study were assessed at their clinical follow-up at 2-4 month corrected age (CA). Their neurodevelopmental outcome was assessed regularly up to 12-31 months CA. GMA was used as the study outcome measure. The GMA was completed by one of the study authors and by a masked GMA-expert of conventional and computed 3D body model ("SMIL motion") videos of the same general movements (GMs). Agreement between both GMAs was tested using dichotomous and graded scaling with Kappa and intraclass correlations, respectively. Sensitivity and specificity to predict cerebral palsy (CP) at  $\geq 12$  months CA were assessed. The authors concluded that this study demonstrates that the amount of motion details captured by the Skinned Multi-Infant Linear Model (SMIL) motion video (based on a Kinect recording and the KineMAT tool) enables accurate GMA at fidgety age. According to the authors, this implies that the SMIL motion video adequately catches the movement characteristics needed for GMA of infants with movements ranging from a normal to a definitely abnormal quality, turning it into an attractive tool for automatic GMA. The authors indicated that study limitations included a small sample size, the inclusion of high-risk infants only, and short follow-up. There is no evidence from this study that the markerless motion capture system will impact patient management.

In a systematic review, Puh et al. (2019) evaluated the validity and reliability of using the Kinect camera (a markerless motion capture system) as an assessment tool for transitional movement and balance. A total of 21 research articles, published from 2012 to 2018, were included in the analysis and qualitative synthesis. Many of the included studies reported validity and did not report reliability, which limited the application to practice. According to the authors, the translation into practice for Kinect is also limited by lack of redundancy among studies and access to the software to implement the tests.

# U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Products used for diagnostic dynamic spinal visualization and vertebral motion analysis are extensive. See the following website for more information and search by product name in device name section:

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmnm.cfm>.

## References

The foregoing Oxford policy has been adapted from an existing UnitedHealthcare national policy that was researched, developed and approved by UnitedHealthcare Medical Technology Assessment Committee. [2022T0633A]

Hurley RJ, Davey MS, Newell M, et al. Assessing the accuracy of measuring leg length discrepancy and genu varum/valgum using a markerless motion analysis system. *J Orthop*. 2021 Jul 13; 26:45-48.

Knippenberg E, Verbrugghe J, Lamers I, et al. Markerless motion capture systems as training device in neurological rehabilitation: a systematic review of their use, application, target population and efficacy. *J Neuroeng Rehabil*. 2017 Jun 24;14(1):61.

Lee SW, Wong KW, Chan MK, et al. Development and validation of a new technique for assessing lumbar spine motion. *Spine*. 2002 Apr 15;27(8): E215-20.

O'Sullivan K, Verschueren S, Pans S, et al. Validation of a novel spinal posture monitor: comparison with digital video fluoroscopy. *Eur Spine J*. 2012 Dec;21(12):2633-9.

Puh U, Hoehlein B, Deutsch JE. Validity and reliability of the Kinect for assessment of standardized transitional movements and balance: systematic review and translation into practice. *Phys Med Rehabil Clin N Am*. 2019 May;30(2):399-422.

Schroeder AS, Hesse N, Weinberger R, et al. General movement assessment from videos of computed 3D infant body models is equally effective compared to conventional RGB video rating. *Early Hum Dev*. 2020 May; 144:104967.

Springer S, Yogev Seligmann G. Validity of the Kinect for gait assessment: a focused review. *Sensors (Basel)*. 2016 Feb 4;16(2):194.

Teyhen DS, Flynn TW, Childs JD, et al. Fluoroscopic video to identify aberrant lumbar motion. *Spine*. 2007; 32(7): E220-229.

van Kersbergen J, Otte K, de Vries NM, et al. Camera-based objective measures of Parkinson's disease gait features. *BMC Res Notes*. 2021 Aug 26;14(1):329.

Yeager MS, Cook DJ, Cheng BC. Reliability of computer-assisted lumbar intervertebral measurements using a novel vertebral motion analysis system. *Spine J*. 2014 Feb 1;14(2):274-81.

## Policy History/Revision Information

Date	Summary of Changes
10/01/2022	<p><b>Template Update</b></p> <ul style="list-style-type: none"><li>Created service-specific policy version for content previously included in the Clinical Policy titled <i>Omnibus Codes</i></li></ul> <p><b>Coverage Rationale</b></p> <ul style="list-style-type: none"><li>Added language to indicate vertebral motion analysis is unproven and not medically necessary due to insufficient evidence of efficacy</li><li>Replaced language indicating “<i>the use of video fluoroscopy, cineradiography, Spinalyzer and similar technology, and digital motion X-rays to diagnose spinal and skeletal dysfunction</i> is unproven and not medically necessary due to insufficient evidence of <i>safety and/or efficacy</i>” with “<i>the following dynamic spinal visualization techniques: digital motion x-ray of the spine and cineradiography/videofluoroscopy, when used to visualize movement of the back or spine, are unproven and not medically necessary due to insufficient evidence of efficacy</i>”</li></ul> <p><b>Applicable Codes</b></p> <ul style="list-style-type: none"><li>Added CPT codes 0693T, 76496, and 76499</li></ul>

Date	Summary of Changes
	<p data-bbox="337 138 639 170"><b>Supporting Information</b></p> <ul data-bbox="337 176 1398 270" style="list-style-type: none"> <li data-bbox="337 176 932 207">• Added <i>Description of Services</i> and <i>FDA</i> sections</li> <li data-bbox="337 212 1398 243">• Updated <i>Clinical Evidence</i> and <i>References</i> sections to reflect the most current information</li> <li data-bbox="337 247 1094 270">• Archived previous policy version ADMINISTRATIVE 212.59 T2</li> </ul>

## Instructions for Use

This Clinical Policy provides assistance in interpreting UnitedHealthcare Oxford standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare Oxford reserves the right to modify its Policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice.

The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. UnitedHealthcare Oxford Clinical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.